Bayer Plans to Separate to Benefit Company Growth
Bayer separates into two entities to benefit the growth and development of Bayer Life Science and MaterialScience.
Bayer announced on Sept. 18, 2014 that it will divide into two global corporations: Bayer Life Science businesses and a separate identity, MaterialScience. The company-wide shift allows Bayer to focus time and the investments needed to sustain the Life Science businesses, which account for 70% of Bayer sales. According to Bayer, the plan to float MaterialScience independently on the stock market grants them direct access to capital for growth and will allow environmental and business development within the company.
Source: Bayer
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
